Elamipretide (SS-31) FDA approval claims: What the evidence actually shows

What did @dracintiaazevedo actually say?

The transcript provided doesn't give us much to work with. The words captured are essentially filler: "I have some and the best way to do it is to make it easier." That's not a coherent medical claim. What we do have is the video caption, which makes a specific assertion worth examining: that elamipretide (SS-31) "just received FDA approval." That's a concrete, verifiable claim, and it's the one we're going to dig into.

To be fair to the creator, caption claims and spoken content don't always match up neatly in short-form video. But 42,500 viewers saw that caption, and many of them are going to walk away believing SS-31 is now a fully approved drug they can ask their doctor about. That framing matters.

Does the science back this up?

The FDA approval claim is, at best, premature. As of early 2025, elamipretide has not received full FDA approval for any indication. What has happened is that Stealth BioTherapeutics conducted Phase 2 and Phase 3 trials for Barth syndrome, a rare mitochondrial disease. The Phase 3 TAZPOWER trial, published by Bertini et al. (2022) in the journal JAMA Cardiology, actually failed to meet its primary endpoint of improved exercise tolerance, which was a significant setback for the drug's regulatory path.

There is a substantial body of preclinical research showing that SS-31, a mitochondria-targeting peptide, reduces oxidative stress and improves ATP synthesis in animal models. Studies like those from Szeto and Birk (2014) in the British Journal of Pharmacology generated real excitement. But animal data and human clinical outcomes are two very different things, and the gap between them has swallowed many promising compounds.

What did they get wrong (or right)?

The FDA approval claim, as stated in the caption, appears to be inaccurate based on publicly available regulatory records. The FDA has granted elamipretide orphan drug designation and fast-track status, which are procedural designations, not approvals. Conflating these with full approval is a meaningful error that could mislead patients into thinking this is a cleared therapeutic option.

To give some credit: the underlying question "does this peptide actually work?" is the right one to ask. The honest answer is that we don't know yet for humans across most applications. The mitochondrial mechanism is scientifically plausible and well-supported in vitro. Researchers like Bhatt et al. (2023) in Circulation Research have continued exploring SS-31 in heart failure models with promising signals. But promising signals in research are not the same as a proven treatment.

The compounded peptide market has latched onto SS-31 heavily, often based on animal and early-phase human data. That's a problem. Compounded SS-31 is not equivalent to any investigational or approved formulation used in clinical trials.

What should you actually know?

Here's what the science actually supports right now. SS-31 works by selectively binding to cardiolipin, a phospholipid in the inner mitochondrial membrane. This interaction appears to stabilize mitochondrial cristae, reduce reactive oxygen species production, and improve electron transport chain efficiency. Those are real, documented mechanisms, studied seriously by institutions including Weill Cornell and the University of Washington.

What this does not mean: SS-31 is not a proven longevity drug. It is not a cleared treatment for heart failure, kidney disease, or aging in humans. Its regulatory status does not currently support the framing of "just approved by the FDA." Anyone offering it via telehealth should be doing so within the context of honest informed consent, acknowledging the experimental nature of the compound and the limitations of the current evidence base.

If you're interested in mitochondrial health and peptide research, that interest is legitimate. But the evidence bar for human use needs to be higher than what one TikTok caption implies.